Crosslinked Multiblock Copolymer Micelles for Anthracycline Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anthracycline formulations, such as liposomal doxorubicin, suffer from significant cardiotoxicity and inadequate shielding from degradation in the bloodstream, limiting their efficacy and bioavailability.
Innovation Solution
Development of crosslinked micelles composed of multiblock copolymers with a hydrophilic poly(ethylene glycol) block, a carboxylic acid-containing poly(amino acid) block, and a hydrophobic poly(amino acid) block, which form a stable and targeted delivery system for anthracyclines, enhancing their circulation time and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If liposomal doxorubicin is used, then cancer treatment efficacy is improved, but cardiotoxicity increases
Solution Approach 1:
The patent segments the drug delivery system into multiple functional components: hydrophilic poly(ethylene glycol) blocks for circulation stability, carboxylic acid-containing poly(amino acid) blocks for targeting, and hydrophobic poly(amino acid) blocks for drug encapsulation. This segmentation allows each component to address specific issues, with the hydrophilic blocks reducing cardiotoxicity while maintaining cancer targeting efficacy.
Solution Approach 2:
The patent applies local quality by creating different functional zones within the micelle structure: the hydrophilic corona provides circulation stability and reduces cardiotoxicity, while the hydrophobic core provides drug encapsulation and release. The carboxylic acid-containing blocks provide localized targeting functionality at the micelle surface.
2Productivity
If conventional anthracycline formulations are used, then therapeutic activity is achieved, but bioavailability is reduced due to degradation in bloodstream
Solution Approach 1:
The patent uses the amphiphilic block copolymer micelle as an intermediary carrier that protects anthracyclines from degradation in the bloodstream. The micelle structure acts as a mediator between the drug and the biological environment, maintaining drug integrity while enabling delivery to cancer cells.
Solution Approach 2:
The patent employs composite materials by combining different poly(amino acid) blocks with specific functional groups (hydrophilic, carboxylic acid-containing, hydrophobic) to create a micelle that simultaneously provides protection from degradation, targeting capability, and drug encapsulation.
3Duration of action of moving object
If polymer micelles are designed with specific block compositions, then circulation time is extended, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying the molecular weights, compositions, and ratios of the different poly(amino acid) blocks to optimize circulation time. By adjusting parameters such as the hydrophilic block length and hydrophobic block composition, the patent extends circulation time while maintaining manufacturability through established polymer synthesis methods.
Data Source
AI summary
The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.